Subject Index

Acetylcholine, 67, 79
ACTH, 63, 104–105, 108, 109, 115, 128–131, 136–138, 181–184
ADHD. *See* Attention-deficit hyperactivity disorder
Adolescents
  behavioral effects of hormones on, 28
  group aggression by, 360–362
  growth and decline of violent behavior in, 192–193
  HR in, 376–379
  late maturation in, 28
  physical and emotional abuse of, 325
  steroid use by, 372–374
  testosterone in, 18, 19, 192, 326
Adoption, aggressiveness and, 240
"Aggression gene," 186, 319
Aggression in children, definition of, 290
Aggressive-hyperactive-impulsive (AHI), 278, 280–283, 286
Agonistic behavior, 62, 325–326
Alcohol
  acute intoxication from, 246–248
  aggressive behavior and, 72, 83
  animals sensitive to, 244, 248
  different beverages of, and types of aggression, 240
  fluoxetine effect on usage of, 92, 93
  and monkeys raised in isolation, 324
  perinatal exposure to, 79
Alcoholics, sons of, 238, 239, 243–246, 248–250
Amphetamines, 68, 91, 92, 248, 291, 293, 324
Anabolic-androgenic steroids (AAS), bodybuilding with, 2–3, 272–274
Androgen receptor (AR), 11–14
Androgens, 20, 78, 326, 339–341
Androgen sensitivity, 9–10
Androstenedione (Δ4-A), 20–23, 26
Anger
  in depressed patients, 300
  fluoxetine's reduction of, 93–94
  time of, in temper tantrums, 31–44
Animal models, value of, 254
Antisocial behavior
  autonomic nervous system in, 46–57
  as choice among alternatives, 218–219
  cortisol and, 20, 24, 27, 170–177, 187
  engaged in by majority of children, 208
  environmental causes of, 310, 312
  hormonal levels in, 18, 20
  persistent, 208–210
  and prenatal nicotine, 109–110, 324–325
  as social crisis, 210, 212, 213
  stable perseveration in, 332–333
Anxiety
  dissolved by drugs, 247–249
  hormonal concentrations and, 20–26
  HR variability and, 376–379
  low, in bullies, 269
  whether predictor of delinquency, 239, 367
Apomorphine, 86, 181–182
AR. *See* Androgen receptor
Arginine vasopressin (AVP). *See* Vasopressin—arginine
Attachment
  adult interview on, 156, 343–345
  aggression and
    children at high risk, 346–347
    children of working poor, 343–345
  consequences of lack of, 322–323
  neural patterning and, 132
Attention-deficit hyperactivity disorder (ADHD), 84, 277–280, 300, 319
  psychopharmacologic intervention in, 291–292, 302
  See also Hyperactive children
Autism, 319
  psychopharmacologic intervention in, 298–299
Autonomic nervous system (ANS)
  effects of aggression on, 62–67
  in human antisocial behavior, 46–57
  in risk for drug abuse, 243–244

Barbiturates, 72, 74
Behavioral modification
  in ADHD case, 319–320
  in classroom vs. home setting, 321–322
  in PDD, 298
Beliefs about aggressive actions and feelings, 329–331
Benzodiazepine-$GABA_A$ receptors, 71–72, 74
Benzodiazepines, 293
Beta-blockers, 84, 293, 295, 298
Biofeedback for low arousal, 56–57
Biological correlates of aggression, 78–81
Biological perspective on violence, 3–7
Biosocial foundations, 253–255
Bipolar depressive illness (BDI), psychopharmacologic intervention in, 300–301, 302
Bodybuilding, 2–3, 372–374
Bomb disposal experts, low HRLs of, 49

Brain
attachment and patterning of, 132
concept of disorganization of, 125–127
neurochemistry of, and aggression, 326–327
perinatal development of, 113, 183–187
perinatal injury to, 79
synapse formation and neuron survival in, 113, 141
See also Central nervous system (CNS); traumatic brain injury
Bullying
definition of, 265–266
friendship networks and, 355–358
as group phenomenon, 360–362, 401–404
intervention vs., 271–275, 399–400, 404
peer perceptions of, 336–338
as question of democracy, 270–271
Buproprion, 292, 300, 302
Buspirone, 295, 298, 299, 302

Carbamazepine, 293, 297, 298, 302
Castration, effects of, 9, 12
Catecholamines, 67, 84–85, 130–131, 136–137, 298
CBG (corticosterone-binding globulin), 105, 183
Central nervous system (CNS)
androgen- and estrogen-sensitivity in, 9–10
pathways of T through, 8–14
in prenatal exposure to steroids, 19
See also Brain
Child abuse. *See* Children—abused and neglected
Children
abused and neglected, 114–115, 186–187, 224–235
biological and behavioral consequences, 322–324
excessive aggression as result, 321
physical abuse correlated with aggression, 405–407
risk of violence, 224–235
bullying of. *See* Bullying
isolated, 113–115, 323–324
language impairment in, 113, 114
learned aggression by, 114–115
marital transition and, 386–388
minority, research on aggression of, 310, 315–316, 318
physically aggressive boys, and puberty, 192–205
quantitative study of aggression in, 62
research involving, 313–315
testosterone-aggression link in, 18, 19, 326
See also Adolescents; Excessively aggressive children; Hyperactive children; Mothers; Parents
Chlorpromazine, 292–294, 297
Cholesterol, serotonin and, effect on aggression, 352–354
Cigarette smoking, 108, 324–325
Circadian rhythms in rat aggression studies, 63, 65, 66
Citalopram, 90, 92
Clomipramine, 299, 302
Clonidine, 292, 293, 299, 302, 303
Clozapine, 294
Clozaril, 294
Cocaine, 68, 248
Coercion traps, 154–155
Conduct disorder (CD)
ADHD combined with, 239
attachment system in, 346
criteria for, 211–212
development of, 257–258
hyperactivity combined with, 277
low HR in, 376
prevention programs for, 256–264
prolactin-fenfluramine response in, 392
psychopharmacologic intervention in, 292–294, 302
response perseveration in, 332
salivary cortisol in, 169–177
whether mental disorder, 169–170, 208–220, 310–311
Coronary disease, fluoxetine in, 94
Corticosteroids, stress reactions patterned by, 179–187
Corticosterone, 63, 108, 141
Cortisol
antisocial behavior and, 20, 24, 27, 170–177, 187
cigarette smoking and, 108
in monkey rearing study, 129
NBAS administration and, 105–107
in pregnant adolescents, 21, 26, 27
T concentrations and, 20
Cosinor analysis, 63, 65
CREBs (cyclic nucleotide response element binding proteins), 146–147
CRF (corticotropin-releasing factor), 104, 108
CRH (corticotropin-releasing hormone), 136–137, 140, 181–182, 184
Criminals
autonomic factors vs. development of, 51–54
former bullies as, 269–270
nonviolent, intermediate HRLs of, 48–49

violent
cortisol in, 170
elevated T levels, 18
frontal lobe impairments, 408
reduced SC orienting, 47–48
whether abused children, 114, 186–187, 224–235
as young as 11 or 12, 308
Criminogenic neighborhoods, 215, 218–219, 312
Cycle of violence, 186, 224, 230–232, 321

Defensive aggression, 360, 362
Defensive reactions to aggression, 63
Delinquency
persistence of, and neuropsychological functioning, 413–416
physically vs. nonphysically aggressive, 200–205
predictors of, 239, 367–368
types of, 413
See also Conduct disorder
Depression
attachment and, 346–347
norepinephrine shortage as cause of, 125
as outcome of girls' aggression, 394–397
psychopharmacologic intervention in, 299–300, 302
DES (diethylstilbestrol), 12, 19, 339–341
Desipramine, 300
DHEA (dehydroepiandrosterone), 20–22, 24
DHEAS (dehydroepiandrosterone sulphate) 20–24, 27
DHT (dihydrotestosterone), 8–9, 11, 339–341
Diagnostic and Statistical Manual of Mental Disorders (DSM), 169, 211–212, 219, 282
Diazepam, 72
Disinhibited temperaments, 50–51, 57
Disinhibition syndrome, 332
Disorder, definition of, 311
Disruptive behavior disorders (DBDs), gender differences in, 369–371
Divorce and children's aggression, 386–388
DNA methylation, 148
Dominance
5-HT and, 122–124
in deprivation-handling studies, 140–141
DOPAC (dihydroxyphenylacetic acid), 68
Dopamine (DA), 68–71, 74, 79, 85, 90, 125, 131
drug abuse and, 248
genetic selection and, 181–182
Drug abuse
boys at risk for, vs. those at risk for aggression, 238–250
by monkeys raised in isolation, 324
Drug treatment. *See* Pharmacotherapeutic intervention
Dysfunction
harmful, 216–218
meaning of term, 210

Electrodermal activity (EDA). *See* Skin conductance
Electroencephalogram (EEG) of sons of alcoholics, 243, 249
Eltoprazine, 98, 181
Emotions
hormonal concentrations and, 20
time course of, 31, 44
See also Anger
Empathy, 249, 322, 364–366, 404
Endotoxins, stress and, 136, 138, 139
Enkephalins, 68, 85
Environment
aggression influenced by, 116
antisocial behavior, 310, 312
vs. heredity, 1–2, 318, 327
nervous system and, 113, 183–187, 324–326
stress response altered by, 136–148, 324–325
Epilepsy. *See* Seizure disorder
Epinephrine, 20
EPR (evoked-potential response), 243
Equifinality, principle of, 215–216
ER. *See* Estrogen receptor
Estradiol (E_2), 8, 20–23, 26, 116
Estrogen receptor (ER)
activation of, and aggression in ERKO mice, 384–385
AF1 and AF2 functions of, 14
in regulation of aggression, 11–14
Estrogens, 78, 339–341
Estrogen-sensitivity in males, 9–10, 12
Ethanol (ETOH), 72, 74, 348–351
Ethopharmacology of aggression, 60–74
Excessively aggressive children
intervention with, 308–316
in psychiatric illness, 319–320
social causes of, 320–321

Family. *See* Children; Mothers; Parents
Family adversity, pain sensitivity and, 409
Fast Track prevention program, 259–264, 322

Fearlessness
in acute alcohol intoxication, 247
low arousal as marker of, 49–50, 51
as possible learned response, 56
Fenfluramine, 91, 92, 298, 302, 327, 369–371, 391–393
Fight/flight response, 104, 179, 180, 239, 361
Fighting as function of personality and neuropsychology, 411–412
Firearm injuries, criminality and morbidity in victims of, 334–335
5-HIAA, 92, 122–132, 214, 240
5-HT. *See* Serotonin
Fluoxetine (Prozac), 90–94, 98–101, 292, 298–300, 302, 326
Fluphenazine, 299
Fluvoxamine, 90, 98, 180
Foster care, and later violence by abused children, 227, 232–233, 234–235
Frontal lobe dysfunction, 295
in alcoholism and aggression, 243, 249
antisocial behavior and, 47, 56
pain perception and, 408

GABA, 67, 71–72, 74, 79, 243, 247, 248
Gangs, 218–219, 360
Gender differences
androgen- and estrogen-sensitivity, 9–10
beliefs about aggression, 329–331
bullying, 266–267, 268, 358, 403–404
conduct disorder, 292
cortisol response to NBAS, 106
density of serotonin innervation, 115
development of aggression, 115–116
disruptive behavior disorders, 369–371
in outcomes of childhood aggression, 394–397
in subsequent crime after abuse, 226, 229–230, 233
in TV violence viewing and aggression, 380–383
Genetic basis of aggression, 116, 182–183, 185–186, 319
in male-typical aggression, 9, 14
Glucocorticoids, 20, 104–105, 115, 136–148, 184, 326
exposure to high levels of, 137
handling and, 138, 141–148, 324
Groups
adolescent aggression and, 360–362
bullying as phenomenon of, 401–404
Guanfacine, 292, 302

Haloperidol, 71, 180, 292–294, 297, 299
Hamster studies, 93, 98, 101, 186, 325–326, 348–351
Handling, 138, 141–148, 184, 324
Heart period variability (HPV), aggression correlated with, 391–393
Heart rate (HR)
in animal aggression studies, 63, 64
human
and antisocial behavior, 47–50, 55, 56, 244–245, 376, 391
desistors from crime, 51–52, 54
inhibited subjects, 50–51, 376
of sons of alcoholics, 249
variability of, and anxiety-aggression relationship, 376–379
Hemicircadian rhythms, in rat aggression studies, 63, 66, 67
Heredity, environment vs., 1–2, 318, 327
Hill, Henry, 219–220
Hostility, fluoxetine and, 93–94
HPA (hypothalamic-pituitary-adrenal) axis, stress response and, 27, 104–108, 130–131, 136–142, 181–185, 324
HPG (hypothalamic-pituitary-gonadal) axis, 18
HRL (heart rate level). *See* Heart rate
HVA (homovanillic acid), 68, 84, 85, 125, 128–130
Hyperactive children
early intervention with, 277–287
possible social causes of, 310, 312
at risk for later delinquency, 367
some bullying victims as, 268
See also Attention-deficit hyperactivity disorder
Hypothalamic-pituitary-thyroid (HPT) axis, 142
Hypothalamus, functional integration of, 186

Imipramine, 300
Indirect aggression, 266, 364–366
Informed consent, 312–315
Inhibition, 50–51, 57, 332, 367–368, 376
Interdisciplinary approach, 1–7
International Committee against Racism, 315, 316
Intervention
with aggressive hyperactive children, 277–287
biological, 254
clinical, pharmacotherapy with, 290–303
in conduct disorder, 256–264, 286–287
ethical issues in, 6–7, 312–315

with excessively aggressive children, 308–316
as nonjudgmental or nonethnocentric, 362
proposed for ages 1 to 3, 322
at school, vs. bullying, 271–275, 399–400, 404
three perspectives for, 6
See also Behavioral modification
Interviews
adult attachment, 156, 343–345
diagnostic, for parents, 282–284

Lithium, 80, 209, 293, 294, 298, 300–302
Longitudinal studies, suggestions for, 254–255
Loxapine, 294

Male-typical aggression, genotypical determination of, 9, 14
Managed health care, quick-fix pressure by, 320
Marital transition and aggression in children, 386–388
Mental disorder
excessively aggressive children and, 319–320
meaning of term, 210
stigma of, 213, 311–312
whether conduct disorder is, 169–170, 211–220, 310–311
Mental retardation (MR), 319
psychopharmacologic intervention in, 297–298, 302
Mesocorticolimbic activity, 60–74
Methylphenidate (MPH), 291–293, 297
Methyltrienolone (R1881), 9–11, 339–341
MHPG (3-methoxy-4-hydroxyphenylglycol), 84–85
Mice studies, 8–14, 19, 68, 71–73, 92, 94, 98, 116, 179–183, 339–341, 384–385
Microdialysis, brain, 91
Minimal brain dysfunction, 310
Minority children, research on aggression of, 310, 315–316, 318
Molindone, 293, 299
Monkey studies, 72, 92–93, 122–133, 179, 185, 254, 323–324, 352–354
Monoamine oxidase (MAO), 116, 183, 186
Monoamine oxidase inhibitor (MAOI), 84, 92, 116, 186, 300
Mothers
child's need for appropriate interactions with, 114, 115
monkeys raised by, vs. peer-raised monkeys, 122, 125–126, 128–133
separation from (maternal deprivation)
Harlow's studies, 323
neurochemistry of, 138, 183–185
See also Children—isolated; Handling; Parents

Nadolol, 298, 299, 302, 303
Naloxone, 67, 85
Naltrexone, 85, 86, 299, 302
Neonates
attending to needs of, 327
estrogen- and androgen-sensitivity in, 9–10
See also Attachment; Children
Neuroleptic medication, 292–295, 297–299, 302, 303
Neurotoxins, 79, 80
Neurotransmitter correlates of human aggression, 82–86
Nicotine, perinatal exposure to, 107–110, 324–325
NIH (National Institutes of Health) panel, 210
NIMH (National Institute of Mental Health), 212
Norepinephrine (NE), 79, 84–85, 90, 125, 128–131, 292
Nortriptyline, 300
Novelty seeking, as predictor of delinquency, 239

Opiates, 85–86
Oppositional defiant disorder (ODD), 277–279, 282, 287, 292, 392
Orienting, SC, 47–49
Oxytocin, 115, 137

Pain
alcoholics and sons sensitive to, 250
low sensitivity to, and stability of aggression, 408–409
Panic disorders, 247, 248
Paranoia, 292, 294
Parents, 153–165
abuse of, and later child abuse, 321
and behavioral modification of children, 321–322
of children with aggressive reaction patterns, 270
personal narratives by, 155–165
proxy consent by, 314–315
social synchrony in, 153–155

training programs for, 156–157, 322
with aggressive hyperactive children, 277–287
in prevention of conduct disorders, 258–264
See also Family adversity; Mothers
Paroxetine, 90, 300
PATHS curriculum, 260, 263
Peer interactions, 114–115, 240
Peer-raised monkeys, 128–133
Pemoline, 291
Peptides, 67, 85–86
Perinatal stress, 79–80, 104–110, 183–187, 254
Pervasive developmental disorders (PDD), psychopharmacologic intervention in, 298–299, 302
Pharmacotherapeutic intervention, 70
clinical approach to, 290–303
lack of knowledge of effect on children, 320
Phenothiazines, 70
Pimozide, 297
Placement outside the home, and later violence by abused children, 227, 232–233, 234–235
Posttraumatic stress disorder (PTSD), psychopharmacologic intervention in, 301, 302
Prefrontal dysfunction. *See* Frontal lobe dysfunction
Pregnancy
cigarette smoking during, 108, 324–325
hormones and behavioral problems in, 18–21, 25–28
stress during, 56
Primate studies, 19, 20, 60, 70, 83, 122–133. *See also* Monkey studies
Prison inmates, hormones in, 20
Problem-solving by parents, 261–262
Progesterone, 72
Prolactin, 181, 186, 326, 369–371, 391–393
Propranolol, 71, 293, 295, 298, 299, 301–303
Prozac. *See* Fluoxetine
Psychomotor exploratory system, 248–249
Psychopathology, meaning of term, 210
Psychopaths, low pain sensitivity of, 408
Psychosocial developmental perspective, 3–7
Psychotic disorders, psychopharmacologic intervention in, 294–295, 302
PTU (propylthiouracil), 142, 146
Puberty
childhood behavioral problems and onset of, 193–205
See also Adolescents

Questionnaires
on beliefs about aggression, 329–331
of boys on school and behavior, 196

R1881. *See* Methyltrienolone
Racism
moral-universals concept as leading to, 362
research and question of, 310, 315–316, 318
Raclopride, 70, 71
Rat studies, 60–61, 63, 67–73, 92, 93, 98, 108, 109, 114–115, 139–148, 179–182, 185, 186, 244, 248
Research
on aggression, politics of, 315–316
ethical issues in, 312–315, 318
Reward dependence, low, 239
Risk factors ("at risk"), 238–239
Risk taking, 83
Risperidone, 294

SC. *See* Skin conductance
Schizoid tendencies, SC orienting and, 47
Schizophrenia, 125, 294
Schools
bullying at. *See* Bullying
teachers' behavior as cause of students' stress, 390
Seizure disorder (epilepsy), psychopharmacologic intervention in, 296–297, 302
Self-injurious behavior (SIB), 85–86, 290, 298, 319, 323
in mental retardation, 297
in PDD, 298, 299
Serotonin (5-HT), 79, 82–86
in androgenic vs. estrogenic systems for aggression, 339–341
cholesterol and, 352–354
fluoxetine effects on, 90–94, 99, 101, 254, 326
gender differences in, 115, 369–371
in genetically altered animals, 116
handling and, 143–148, 324
low levels of, and violence, 121–124, 133, 214, 254, 311, 326–327
motivational states and, 243
and prenatal nicotine, 109, 324
in risk for drug abuse and aggression, 240–243
vasopressin suppressed by, 98–101
Serotonin-reuptake inhibiting agents, 303, 326
Sertraline, 90, 98, 300

Sex differences. *See* Gender differences
Sexual intercourse
  first, 196, 199–200, 202–205
  rejected by totally isolated female monkeys, 323
SHRP (stress hyporesponsive period), 105, 107, 110, 183–184
Skin conductance (SC); electrodermal activity (EDA)
  in antisocial and aggressive behavior, 46–50, 55, 170, 214
  in desistors from crime, 51–54
  in uninhibited children, 51
Social environmental perspective on violence, 3–7, 320–321
Spouse abuse, 233
SSRIs (selective serotonin uptake inhibitors), 116, 300, 302
Steroid receptor (SR), 8–9, 11, 12
Steroids
  in animal aggression studies, 67
  neuroactive, 72, 74
Stimulant medications, 291, 293, 296–300, 302, 320
Stimulation seeking, low arousal as marker of, 50, 57
Stress
  definition of, 104
  family, 240
  hormone levels and, 19–20, 27
  hormones associated with, 63, 179–187, 324
  HPA axis and, 27, 104–108, 130–131, 136–142, 181–185, 324
  novelty, 68
  perinatal, 79–80, 104–110, 183–187, 254
  PTSD after, 301
  reduced autonomic activity and, 56, 57
  relationship of aggression to, 179, 326
  shock, in adolescent hamsters, 348–351
  social defeat, 68–69
Stress dampening, 244, 247–248
Submissive reactions to aggression, 63

T. *See* Testosterone
Tamoxifen, 14
"Tantrugrams," 34
Television violence viewing and aggression in females, 380–383
Temper tantrums
  biological correlates of, 78–81
  time course of anger in, 31–44
Testosterone (T)
  in adolescent antisocial behavior, 20–23, 26–27, 192, 205
  aggression in humans and, 18–20
  in bodybuilding, 372
  brain implants of, 12
  chronic exposure of females to, 9
  cortisol moderation of effects of, 20
  daily variability of levels of, 27
  major metabolites of, 8
  in male-typical aggression, 8–14
  and prenatal nicotine, 109
Thioridazine, 292–294, 297
Thiothixene, 294, 299
Thyroid hormones, handling and, 142–143
Tourette's syndrome, 319
Traumatic brain injury (TBI), psychopharmacologic intervention in, 295–296, 302
Trazodone, 293, 296, 302
Tree-shrew studies, 63, 179, 185
Tricyclic antidepressants (TCA), 84, 90, 292, 297, 300, 302
Trifluoperazine, 299
Tryptophan, 92, 93, 116, 240–241
Twin studies, 20, 116

Ultrasonic vocalization in rats, 63, 114, 139
Unipolar depression, 293, 302
"Usual behavior," whether aggression is, 124–125

Valproic acid, 302
Vasopressin, 79, 86, 109, 326–327
  arginine (AVP), 98–101, 136–138
Violence Initiative, 209, 210, 315–316
Violent behavior (violence)
  adolescent growth and decline in, 192–193
  alcohol intoxication and, 246
  American search for solution to, 208–211
  child abuse as leading to, 114–115, 186–187, 224–235
  connection between psychosis and, 294
  environment vs. biology as cause of, 318, 327
  legal responsibility for, 80, 308
  questionnaire on, 196
  so-called federal draconian approach to, 209–210, 315–316
  societal approval of, 80, 312
  See also Criminals—violent; Excessively aggressive children
Violent films, HR and watching of, 56

Index of Contributors

Archer, J., 329–331
Arseneault, L., 332–333, 376–379

Barkley, R. A., 277–289
Barrett, S., 277–289
Bates, M. E., 413–416
Bell, R., 336–338
Bergman, B., 334–335
Bierman, K. L., 256–264
Biesecker, G., 346–347
Björkqvist, K., 364–366
Blustein, J., 308–317
Boulerice, B., 332–333, 386–389, 408–410
Brewer, J., 348–351
Brismar, B., 334–335

Capasso, L., 169–178
Clarke, A. S., 121–135
Coccaro, E. F., 82–89
Collins, K., 336–338
Cologer-Clifford, A., 8–17, 339–342
Connor, D. F., 290–307
Constantino, J. N., 343–345
Coplan, J., 391–393
Crosswait, C., 277–289

Davidson, R. J., 31–45
de Kloet, E. R., 179–191
Diorio, J., 136–152

Earls, F., 376–379
Easterbrooks, M. A., 346–347
Eichelman, B., 78–81

Ferris, C. F., 98–103, 318–328, 348–351, 372–375
Fletcher, K., 277–289
Fontenot, M. B., 352–354
Francis, D., 136–152
Fried, J., 391–393
Fuller, R. W., 90–97

Gartner, J., 113–120
Granger, D. A., 18–30
Greenhill, L., 391–393
Grisso, T., 1–7

Haigh, A., 329–331
Halperin, J. M., 369–371
Harden, P. W., 408–410
Hartwig, A. C., 78–81
Hornig, C. D., 411–412
Huesmann, L. R., 380–383, 394–398
Huttunen, A., 355–359

Jacobson, K., 360–363
Jenkins, L., 277–289

Kaplan, J. R., 352–354
Kaukiainen, A., 364–366
Kerr, M., 367–368
Kindlon, D., 376–379
King, J. A., 104–112
Koda, V. H., 369–371
Kolko, D. J., 405–407
Korach, K. S., 384–385
Korte, S. M., 179–191
Kosorok, M. R., 31–45
Kraemer, G. W., 121–135
Kruk, M. R., 179–191

Lagerspetz, K. M. J., 355–359, 364–366, 401–404
Lahey, B. B., 169–178
LaPlante, P., 136–152
Loeber, R., 169–178
Lu, S-f., 8–17
Lubahn, D. B., 384–385

Mann, J. J., 352–354
Manuck, S. B., 352–354
Maxfield, M. G., 224–237
McBurnett, K., 169–178
McCord, J., 253–255
McKay, K. E., 369–371
McKenna, S. E., 8–17
Meaney, M. J., 136–152
Melloni Jr., R. H., 372–375
Metevia, L., 277–289
Mezzacappa, E., 376–379
Miczek, K. A., 60–77
Moise, J. F., 380–383
Moorehouse, M., 277–289
Murowchick, E., 18–30
Myers, M., 391–393

Newcorn, J. H., 369–371

Ogawa, S., 384–385
Olweus, D., 265–276
Ondrová, K., 399–400
Österman, K., 364–366

Pagani-Kurtz, L., 367–368, 386–389
Parsons, B., 391–393
Peterson, J. B., 238–252, 411–412
Pfaff, D. W., 384–385
Piekarska, A., 390
Pihl, R. O., 238–252, 376–379, 408–410, 411–412
Pine, D. S., 391–393
Podolski, C-L., 394–398
Ponirakis, A., 18–30
Ponzer, S., 334–335
Potegal, M., 31–45

Raine, A., 46–59
Říčan, P., 399–400
Richters, J. E., 208–223
Rots, N. Y., 179–191

Salmivalli, C., 355–359, 401–404
Saul, J. P., 376–379
Scarpa, A., 405–407
Schaal, B., 192–207
Schwartz, S. T., 369–371
Seckl, J. R., 136–152
Séguin, J. R., 408–410, 411–412
Shaffer, D., 391–393
Shelton, T. L., 277–289
Shively, C. A., 352–354
Simon, N. G., 8–17, 339–342
Sloan, R., 391–393
Smoluk, S. A., 339–342
Steingard, R. J., 290–307
Susman, E. J., 18–30
Svatoš, J., 399–400

Tornatzky, W., 60–77
Tremblay, R. E., 192–207, 332–333, 367–368, 376–379, 386–389, 408–410, 411–412

Vickers, K. E., 411–412
Vitaro, F., 367–368, 386–389

Wahler, R. G., 153–168
Wasserman, G., 391–393
Weaver, S., 136–152
Whitaker-Azmitia, P. M., 113–120
White, H. R., 413–416
Widom, C. S., 224–237
Worrall, B. K., 18–30